Liver disease induced coagulopathy: Difference between revisions

No edit summary
Line 1: Line 1:
==Background==
==Background==
==Clinical Features==
==Differential Diagnosis==
{{Increased bleeding DDX}}
==Diagnosis==
*PT prolongation
*PT prolongation
**Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)
**Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)
Line 26: Line 34:
**Use with caution; requires large volume of FFP to make a significant difference
**Use with caution; requires large volume of FFP to make a significant difference
*PPI/pepcid/octreotide (variceal bleed)
*PPI/pepcid/octreotide (variceal bleed)
==Disposition==


==See Also==
==See Also==
*[[Coagulopathy (Main)]]
*[[Coagulopathy (Main)]]


==Source==
==References==
*Tintinalli
*UpToDate


[[Category:Heme/Onc]]
[[Category:Heme/Onc]]

Revision as of 12:47, 10 June 2015

Background

Clinical Features

Differential Diagnosis

Coagulopathy

Platelet Related

Factor Related

Diagnosis

  • PT prolongation
    • Decreased synthesis of vitamin K-dependent factors (II, VII, IX, X)
  • Thrombocytopenia
    • Portal hypertension -> congestive hypersplenism -> splenic sequestration
  • Fibrinolysis increased
    • Due to decreased synthesis of alpha2 plasmin inhibitor
    • Low fibrinogen level, mild elevation of FDP and D-dimer

Treatment

Lab abnormalities only (w/o significant bleeding)

  • Observation

Significant bleeding

  • Vitamin K PO or IV
  • Desmopressin
    • Effective w/ minimal side effects
    • 0.3 mg/kg IV (preferred) or SC (max 20mg)
    • Onset of action ~1hr, duration of action ~4-24hr
  • Cryoprecipitate
    • May be used to replace fibrinogen in pts w/ fibrinogen levels <100
    • 1 bag per 10kg of body weight
  • Platlets
    • Aim for >50K for moderate risk procedures; >100K for high risk procedures
  • FFP
    • Use with caution; requires large volume of FFP to make a significant difference
  • PPI/pepcid/octreotide (variceal bleed)

Disposition

See Also

References